Merck Sharp + Dohme Corp.

Kevin Caili Wangr

Yan Li

Peter Peizhi Luo

Pingyu Zhong

Andrei Alexandrovich Golosov

Feng Dong

Rose M Cubbon

Jon H Condra

Weirong Wang

Xinwei Wang

Mark Hsieh

Laurence B Peterson

Yan Ni

Noel Byrne

Sujata Sharma

Jun Lu

Gopalakrishnan Parthasarathy

Stephen Soisson

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

AX132 PCSK9 antagonists

Growing community of inventors

Lansdale, PA, United States of America

Kevin Caili Wangr